Bionomics’ (BNOX) “Outperform” Rating Reiterated at William Blair

Bionomics (NASDAQ:BNOX)‘s stock had its “outperform” rating restated by stock analysts at William Blair in a research report issued to clients and investors on Friday,RTT News reports.

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Bionomics in a report on Thursday, August 1st.

Bionomics Stock Up 8.2 %

Shares of BNOX opened at $0.32 on Friday. The stock has a 50-day moving average of $0.40 and a two-hundred day moving average of $0.64. Bionomics has a one year low of $0.18 and a one year high of $2.19.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bionomics stock. Armistice Capital LLC acquired a new position in shares of Bionomics Limited (NASDAQ:BNOX) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned 15.03% of Bionomics at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.90% of the company’s stock.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.